8th Feb 2021 15:18
RTW Venture Fund Ltd - New York-based investment company focussed on life sciences - Portfolio firm Immunocore Inc prices upsized USD253.8 million initial public offering and lists on Nasdaq Global Market.
Immunocore offered 9.9 million shares at a share of USD26 each to raise USD258.3 million.
The company is focused on the development of a class of T-cell receptor bispecific immunotherapies for the treatment of a broad range of diseases, including cancer, infectious and autoimmune diseases.
Goldman Sachs & Co LLC, JP Morgan Securities LLC and Jefferies LLC acted as joint book-running managers for the offering.
Current stock price: USD2.34
Year-to-date change: up 25%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Rtw Biotech